G-Quadruplexes Modulate TDP-43 Aggregation and Toxicity

Protein condensation and aggregation are central features of several neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration. The 2025 Structure study by Oldani and colleagues examines whether G-quadruplexes, or G4s, directly influence the behavior of trans-active response DNA-binding protein 43 kDa (TDP-43). Its importance lies in connecting a defined RNA secondary structure with TDP-43 condensation and toxicity rather than treating nucleic acids as passive binding partners. The reference study combines biophysical experiments with yeast, HEK293T, and motor-neuron-like NSC-34 cell models.

Study Background and Research Question

TDP-43 is an RNA-binding protein involved in RNA processing, transport, and regulation. It is primarily nuclear but also occurs in the cytoplasm under physiological conditions. In ALS and related disorders, TDP-43 can redistribute and form abnormal inclusions. Although wild-type TDP-43 aggregation is a defining feature of most sporadic ALS, the molecular events that initiate or sustain this process remain incompletely understood.

Several earlier observations suggested that RNA could act as a chaperone for TDP-43. Long non-coding RNA, lariat introns, and short TDP-43-binding oligonucleotides have each been associated with reduced toxicity or altered aggregation in selected models. TDP-43 also binds G4s, which are four-stranded nucleic-acid structures formed when guanine-rich sequences assemble into stacked tetrads. RNA G4s are particularly relevant because cellular stress can increase their formation, and stressed cells are also more prone to abnormal protein condensation.

The central question was therefore whether G4s merely bind TDP-43 or whether they actively modify its aggregation, intracellular distribution, and toxicity. The authors addressed this question across distinct experimental levels: purified or reconstituted protein assays, yeast, human embryonic kidney cells, and motor-neuron-like cells.

Key Innovation from the Reference Study

The study’s main innovation is its integrated treatment of G4s as regulators of TDP-43 phase behavior. Rather than focusing only on whether TDP-43 recognizes a G4 sequence, the authors test how G4 availability and chemical stabilization affect condensation under stress. This is a meaningful shift because a nucleic-acid ligand interaction can have different consequences depending on whether it promotes soluble transport, reversible condensation, persistent aggregation, or cellular clearance.

A second innovation is the use of complementary models. The in vitro experiments ask whether G4s can directly affect TDP-43 aggregation. Yeast experiments examine how G4 exposure relates to cell survival. HEK293T assays test stress-induced condensation and the effect of G4-binding small molecules. NSC-34 experiments provide a more neuron-relevant context in which TDP-43 toxicity and G4 co-localization can be evaluated together. According to the published report, the direction and consequence of G4 modulation depend on the biological context, but the overall relationship is consistent: G4s are active participants in TDP-43 behavior.

Methods and Experimental Design Insights

The experimental design is valuable because it separates direct biochemical effects from cell-dependent responses. The in vitro arm tests whether G4 nucleic acids can alter aggregation of eGFP-tagged TDP-43. The cellular arms then examine whether similar relationships are visible when stress, proteostasis, and endogenous cellular organization are present.

Protocol Parameters

The following parameters summarize the study design reported in the reference article. They are experimental features to reproduce conceptually, not a substitute for the authors’ complete procedures.

• Biophysical substrate: use a defined G4-forming nucleic-acid substrate with purified or reconstituted eGFP-TDP-43 to test direct effects on aggregation.
• Protein readout: distinguish aggregation or condensation from simple nucleic-acid binding, since the same interaction can produce different material states.
• Cellular models: compare Saccharomyces cerevisiae, TDP-43-expressing HEK293T cells, and TDP-43-overexpressing NSC-34 motor-neuron-like cells.
• Stress conditions: evaluate TDP-43 distribution during proteasomal or oxidative stress in the human-cell assays, rather than interpreting unstressed localization as a complete disease model.
• G4 perturbation: compare direct G4 treatment or G4-binding small molecules with appropriate untreated and stress controls, while monitoring both structure-related and TDP-43-specific outcomes.
• Cellular readouts: assess TDP-43 accumulation, condensation, co-localization with G4s, and toxicity as separate endpoints because increased accumulation does not automatically mean increased cell death.

This layered design also helps identify where an effect originates. A change observed with purified components supports a direct biochemical mechanism. A change that appears only in cells may instead depend on RNA metabolism, proteostasis, stress signaling, or compartmental organization.

Core Findings and Why They Matter

G4s directly modulate TDP-43 aggregation in vitro

The authors first show that G4s can modify TDP-43 aggregation in a reconstituted setting. This result establishes that G4-dependent regulation is not solely an indirect consequence of transcriptional changes or cell stress. At the same time, the study does not reduce the relationship to a single universal outcome. G4 sequence, topology, concentration, protein state, and solution conditions can all influence whether a nucleic-acid interaction favors a particular condensate or aggregate state.

G4 exposure changes TDP-43 behavior in yeast

In yeast, G4 treatment increases TDP-43 accumulation before cellular death and improves the cells’ tolerance of TDP-43. This is an important distinction. More visible intracellular TDP-43 does not necessarily indicate greater toxicity; in this setting, accumulation may represent a less damaging or more manageable state than an alternative form of misfolded protein. The observation supports a model in which nucleic acids can redistribute toxic protein species without simply eliminating them.

G4-binding molecules reduce stress-induced condensation in HEK293T cells

In HEK293T cells expressing TDP-43, G4-binding small molecules increase G4 stability and stabilize TDP-43 while reducing condensation induced by proteasomal or oxidative stress. The result is particularly relevant to proteostasis research because it links a structural RNA perturbation with a stress-sensitive protein phenotype. It also suggests that stabilizing a G4 is not equivalent to forcing more TDP-43 into an irreversible aggregate. Under the reported conditions, the chemical perturbation is associated with less stress-induced condensation.

G4s co-localize with TDP-43 condensates in motor-neuron-like cells

The NSC-34 experiments extend the findings into a motor-neuron-like model. Under stress, G4s co-localize with TDP-43 condensates, indicating that these structures occupy related cellular compartments or material states. Treatment with G4-binding molecules decreases TDP-43-mediated toxicity in this model. Together with the biochemical and yeast results, this supports the authors’ proposal that targeting selected RNA structures could influence protein-misfolding phenotypes.

Why this cross-domain matters, maturity, and limitations

The work broadens the relevance of G4 biology beyond its established roles in telomere biology research and DNA secondary structure research. G4-focused chemistry is also studied in the search for a cancer cell growth inhibitor and in anticancer drug development, but the reference study examines a different endpoint: RNA structure, TDP-43 condensation, and neuronal toxicity. This cross-domain connection is scientifically useful because it suggests that G4-binding chemistry may provide experimental tools for neurodegeneration research. However, the connection remains mechanistic and preclinical rather than therapeutic.

DNA G4s and RNA G4s can differ in sequence context, folding behavior, cellular localization, and interactions with proteins. Therefore, activity against a DNA G-quadruplex cannot be assumed to reproduce the same effect on an RNA G4 or on TDP-43. Any transfer from G4 chemistry used in telomere or cancer studies to TDP-43 models should include direct confirmation of the relevant RNA structure and independent measurements of TDP-43 condensation and viability.

Comparison with Existing Internal Articles

The available internal workflow articles approach G4 research from a practical assay-development perspective. The workflow guide on G4 research emphasizes dose-controlled cell assays, controls, and interpretation of stabilization experiments. That practical emphasis complements the reference study, which supplies the biological rationale for measuring G4-dependent TDP-43 distribution and toxicity rather than G4 abundance alone.

A second applied G4 workflow article connects structure-stabilization experiments with cancer and neurodegeneration applications. Its value is procedural, whereas Oldani et al. provide the primary evidence that G4s co-localize with TDP-43 condensates and that G4-binding ligands can reduce toxicity in selected cellular models. Neither internal article should be treated as evidence that a DNA-focused stabilization experiment automatically reproduces the paper’s RNA G4 mechanism.

Limitations and Transferability

Several limitations define how the findings should be used. First, the models differ substantially in protein expression, cellular organization, stress response, and proteostasis capacity. Yeast tolerance, HEK293T condensation, and NSC-34 toxicity are complementary but not interchangeable endpoints. The results therefore support a conserved experimental relationship between G4s and TDP-43, not a single quantitative response that applies to every cell type.

Second, the cellular experiments include TDP-43 expression or overexpression systems. These are useful for generating measurable phenotypes, but they may produce protein concentrations or distributions that differ from those in patient-derived neurons. Further work is needed to determine how endogenous TDP-43, disease-associated stress, and native RNA processing alter the observed relationship.

Third, G4-binding small molecules are pharmacological probes, not definitive proof that every phenotype results only from G4 stabilization. Compound selectivity, intracellular concentration, membrane access, RNA binding, and off-target effects must be assessed in each model. The study supports G4 modulation as a testable mechanism, but it does not establish clinical efficacy or identify a ready-to-use treatment for ALS.

Finally, increased G4 stability can have different consequences depending on the structure being stabilized. A useful follow-up experiment should therefore measure the targeted G4 state, TDP-43 localization or condensation, and cell survival in the same assay framework. This is more informative than relying on a single fluorescence or viability endpoint.

Research Support Resources

For related G4-stabilization workflows, researchers can use Pyridostatin (SKU A3742), a synthetic G-quadruplex stabilizer commonly supplied as Pyridostatin TFA. It can support DNA G4 and telomere-oriented assay development, but its activity in RNA G4–TDP-43 systems should be validated directly rather than inferred from the reference study, which does not establish that this compound was used.